# US 2016/0256496 A1 · Pharmaceutical composition and method for the treatment of orthopedic pathologies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256496 A1
- Document ID: US20160256496A1
- Status: Published application
- Kind: A1
- Application number: 15/061,606
- Filed: 2016-03-04
- Published: 2016-09-08
- Earliest claimed: 2009-12-11
- Assignees: SCARCELL Therapeutics
- Applicants: Scarcell Therapeutics
- Inventors: Bruno GOGLY; Antoine LAFONT; Bernard COULOMB
- Web page: https://patentgrep.com/patent/US20160256496A1

## CPC

- A61K 35/33: Fibroblasts
- A61K 35/32: Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a gingival fibroblast-derived product and its use in methods for the prevention or treatment of orthopedic pathologies in an individual.

## Claims

### Claim 1

A method for the prevention or treatment of an orthopedic pathology of an individual, comprising administering a prophylactically or therapeutically effective amount of a gingival fibroblast-derived product to said individual wherein the fibroblast-derived product is selected from the group consisting of gingival fibroblast whole cells, a gingival fibroblast conditioned medium, a gingival fibroblast culture, and a gingival fibroblast extract.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the orthopedic pathology is selected from the group consisting of an osteoarticular orthopedic pathology, a muscular orthopedic pathology, a ligamentary orthopedic pathology and a tendinous orthopedic pathology.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the orthopedic pathology is an osteoarticular pathology.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the orthopedic pathology is an inflammatory osteoarticular pathology.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the orthopedic pathology is rheumatoid arthritis or osteoarthritis.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the gingival fibroblast-derived product is injected at a site of orthopedic defect of the individual.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the gingival fibroblast-derived product comprises gingival fibroblast whole cells.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the gingival fibroblast-derived product is a gingival fibroblast conditioned medium.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the gingival fibroblast-derived product is a gingival fibroblast culture.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the gingival fibroblast-derived product is a gingival fibroblast extract selected from the group consisting of a membrane extract, a cytoplasmic extract and a nuclear extract.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the gingival fibroblast-derived product is obtained from gingival fibroblasts which have not undergone a differentiation into cells having an osteogenic phenotype.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the gingival fibroblast-derived product is obtained from gingival fibroblasts taken from the individual.
